Tony Arulanandam

Company: Synaptimmune Therapeutics

Job title: CEO and Founder

Seminars:

Next Generation of Dual Antigen IDR-CAR-T cells for Autoimmune Diseases 2:30 pm

• Discussing increased potency, sensitivity and complete immune reset of dual antigen targeting IDR-CAR-T cells • Proof of concept data for SLE and other autoantibodymediated autoimmune indications targeting B and T-cells • Development of best-in-class next generation of immune cell depleting CAR-T cells and tissue or organ system modulating CAR-Tregs NEW DATARead more

day: Day One Track A, PM